Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel

MLA

Shinji Ohno, et al. “Predictive Impact of Absolute Lymphocyte Counts for Progression-Free Survival in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer Treated with Pertuzumab and Trastuzumab plus Eribulin or Nab-Paclitaxel.” BMC Cancer, vol. 18, no. 1, Oct. 2018, pp. 1–7. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b2a46dede206204bd9e06744d6cea4a4&authtype=sso&custid=ns315887.

APA

Shinji Ohno, Hirofumi Suwa, Yasuo Miyoshi, Yoshimasa Miyagawa, Ayako Kira, Chiyomi Egawa, Yoshinori Ito, Kokoro Kobayashi, Ippei Fukada, Yuichi Takatsuka, Kazuhiro Araki, & Michiko Imamura. (2018). Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer, 18(1), 1–7.

Chicago

Shinji Ohno, Hirofumi Suwa, Yasuo Miyoshi, Yoshimasa Miyagawa, Ayako Kira, Chiyomi Egawa, Yoshinori Ito, et al. 2018. “Predictive Impact of Absolute Lymphocyte Counts for Progression-Free Survival in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer Treated with Pertuzumab and Trastuzumab plus Eribulin or Nab-Paclitaxel.” BMC Cancer 18 (1): 1–7. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b2a46dede206204bd9e06744d6cea4a4&authtype=sso&custid=ns315887.